Swiss Hospitality Stock News

SWX:STMN
SWX:STMNMedical Equipment

3 European Stocks That May Be Trading Below Their Intrinsic Value By Up To 32.5%

Amid heightened uncertainty and inflation risks, European markets have experienced a decline, with the STOXX Europe 600 Index falling by 3.79% due to geopolitical tensions and soaring energy costs. As investors navigate these turbulent times, identifying stocks that may be trading below their intrinsic value could offer potential opportunities for those looking to capitalize on market inefficiencies.
SWX:VAHN
SWX:VAHNInsurance

European Dividend Stocks To Consider Now

As European markets navigate heightened geopolitical tensions and soaring energy costs, investors are increasingly focused on the potential impact of these factors on inflation and economic stability. In this uncertain environment, dividend stocks may offer a measure of resilience by providing regular income streams that can help cushion against market volatility.
SWX:STMN
SWX:STMNMedical Equipment

European Growth Companies Backed By Insider Confidence

As European markets navigate the challenges of heightened energy prices and geopolitical tensions, investors are increasingly focused on companies that demonstrate resilience and potential for growth. In such uncertain times, stocks with high insider ownership can signal strong confidence from those who know the business best, making them attractive candidates for consideration in a volatile market environment.
SWX:BCGE
SWX:BCGEBanks

Assessing Banque Cantonale De Genève (SWX:BCGE) Valuation After Full Year 2025 Earnings Results

Earnings event puts Banque Cantonale de Genève in focus Banque Cantonale de Genève (SWX:BCGE) has drawn fresh attention after reporting full year 2025 results, with net interest income of CHF 347.8 million and net income of CHF 220.89 million. See our latest analysis for Banque Cantonale de Genève. The earnings release comes after a strong run in the share price, with a 90 day share price return of 34.17% and a year to date share price return of 30.89% at a latest share price of CHF32.2,...
SWX:NWRN
SWX:NWRNPharmaceuticals

Newron Pharmaceuticals (SWX:NWRN) Near Breakeven EPS Rekindles Debate On Rich P/S Multiple

Newron Pharmaceuticals (SWX:NWRN) has opened FY 2025 with first half revenue of €11.9 million and a basic EPS loss of €0.00, setting a cautious tone against a share price of CHF 14.64. Over recent periods, the company has seen revenue move from €3.4 million in H1 2024 to €48.0 million in H2 2024 and then to €11.9 million in H1 2025. Basic EPS has shifted from a loss of €0.51 in H1 2024 to a profit of €1.37 in H2 2024 and back to a marginal loss in the latest half, leaving investors focused on...
SWX:SKAN
SWX:SKANLife Sciences

SKAN Group (SWX:SKAN) Margin Slump To Loss In H1 2025 Tests Premium P/E Narrative

SKAN Group (SWX:SKAN) has just posted a softer first half for FY 2025, with revenue of CHF134.6 million and a basic EPS loss of CHF0.40, after generating CHF163.7 million in revenue and EPS of CHF0.61 in the first half of FY 2024. Over the last twelve months, revenue has run at CHF333.3 million with basic EPS of CHF0.72. This latest half-year print lands against a backdrop of shrinking trailing net margins, which keeps the focus squarely on how quickly profitability can stabilise. See our...
SWX:MCHN
SWX:MCHNMedia

MCH Group (SWX:MCHN) EPS Rebound To CHF 0.17 Tests Cautious Debt Narratives

MCH Group (SWX:MCHN) has opened FY 2025 with half year revenue of CHF 214.2 million and basic EPS of CHF 0.17, while trailing twelve month figures sit at CHF 401.6 million of revenue and basic EPS of CHF 0.15 as the company builds on its recent move into profitability. Over the past reported periods, revenue has moved from CHF 233.8 million in the first half of 2024 to CHF 187.4 million in the second half of 2024 and then to CHF 214.2 million in the first half of 2025. Over the same periods,...
SWX:IFCN
SWX:IFCNElectronic

INFICON Holding (SWX:IFCN) Margin Decline Challenges Bullish Growth Narratives In FY 2025 Results

INFICON Holding FY 2025 Earnings Snapshot INFICON Holding (SWX:IFCN) has posted its FY 2025 results with second half revenue of US$348.0 million and basic EPS of US$1.74, alongside net income of US$42.6 million, setting the tone for how the year closed out. The company has seen revenue move from US$349.8 million and basic EPS of US$2.48 in 2H 2024 to US$348.0 million and US$1.74 in 2H 2025, while trailing twelve month revenue sits at US$673.7 million with EPS of US$3.51, giving a clear read...
SWX:NOVN
SWX:NOVNPharmaceuticals

Is Novartis (SWX:NOVN) Fairly Priced After Recent Share Volatility And Solid Earnings Growth

Recent share performance and business scale Novartis (SWX:NOVN) shares recently closed at CHF 117.48, with a 1 day return of 1.17% and mixed short term moves, including a 3.53% decline over the past week and a 7.10% decline over the past month. Over longer periods, the stock shows a 6.70% total return over the past 3 months, 8.28% year to date, and 23.68% over the past year, with multi year total returns also in positive territory. The company reports revenue of CHF 56.67b and net income of...
SWX:CFT
SWX:CFTCapital Markets

Is Compagnie Financière Tradition (SWX:CFT) Attractive After Its Strong Three Year Share Price Gain

If you are wondering whether Compagnie Financière Tradition is attractively priced today, the recent share performance gives some useful clues about how the market currently views the stock. The share price closed at CHF 265.0, with a 4.0% decline over the last 7 days and a 1.5% decline over 30 days, while longer term returns sit at 34.4% over 1 year and 161.2% over 3 years. Recent coverage has focused on Compagnie Financière Tradition in the context of its share price returns and broader...
SWX:HUBN
SWX:HUBNElectrical

European Stocks That May Be Priced Below Their Estimated Value

As European markets face heightened uncertainty due to geopolitical tensions and rising energy costs, the STOXX Europe 600 Index has seen a decline of 3.79%, reflecting investor caution. In this environment, identifying stocks that are potentially undervalued can be an effective strategy for investors looking to capitalize on discrepancies between current market prices and intrinsic value estimates.
SWX:HOLN
SWX:HOLNBasic Materials

European Growth Stocks With Strong Insider Ownership March 2026

As European markets navigate heightened uncertainty stemming from geopolitical tensions and rising energy costs, investors are increasingly focusing on companies with strong fundamentals and insider confidence. In this environment, growth stocks with substantial insider ownership can offer a unique perspective on potential resilience and alignment of interests between management and shareholders.
SWX:LOGN
SWX:LOGNTech

Logitech International’s Valuation After New US$1.4b Buyback Plan And Logitech G RS H Shifter Launch

Logitech International (SWX:LOGN) has drawn fresh attention after announcing a share repurchase plan of up to US$1.4b, alongside the global launch of its Logitech G RS H-Shifter for sim racing enthusiasts. See our latest analysis for Logitech International. The share repurchase news comes after a mixed stretch for the stock. A 2.11% 1-day share price return contrasts with a 7-day decline of 4.33%. Meanwhile, the 3-year total shareholder return of 55.50% stands out against a weaker 1-year...
SWX:TECN
SWX:TECNLife Sciences

Assessing Tecan Group (SWX:TECN) Valuation After New NVIDIA AI Collaboration News

AI-focused partnership shifts attention toward Tecan Group stock Tecan Group (SWX:TECN) has drawn renewed attention after announcing a collaboration with NVIDIA to integrate GPU-accelerated AI models into its laboratory instruments, with the aim of supporting data driven labs and higher research productivity. See our latest analysis for Tecan Group. The AI partnership headlines arrive after a volatile stretch for the stock, with a 1-day share price return of 9.07% and a 30-day share price...
SWX:ABBN
SWX:ABBNElectrical

Assessing ABB (SWX:ABBN) Valuation After Dividend Increase And New Bond Issue

Dividend increase and bond issue draw fresh attention to ABB (SWX:ABBN) ABB (SWX:ABBN) is on income investors’ radar after its board approved a higher dividend of CHF 0.94 per share at the March 19, 2026 AGM, alongside a new fixed income issuance. See our latest analysis for ABB. Those dividend and bond announcements come after a mixed few weeks for the share price, with a 1 day share price return of 1.02% but a 30 day share price decline of 6.89%, set against a 36.48% 1 year total...
SWX:BEKN
SWX:BEKNBanks

A Look At Berner Kantonalbank (SWX:BEKN) Valuation After Weaker Full Year 2025 Results

Earnings trigger puts Berner Kantonalbank in focus Berner Kantonalbank (SWX:BEKN) has drawn investor attention after publishing its full year 2025 results, which show lower net interest income and net income and indicate slightly weaker profitability compared with the previous year. See our latest analysis for Berner Kantonalbank. The earnings release comes after a strong rebound in the share price, with a 10.78% 1 month share price return and 29.04% 3 month share price return, contributing...
SWX:UBSG
SWX:UBSGCapital Markets

Assessing UBS Group (SWX:UBSG) Valuation After US National Banking Licence Approval

UBS Group (SWX:UBSG) has secured final approval for a US national banking licence, a regulatory step that allows the Swiss group to add everyday banking products alongside its existing US wealth management offerings. See our latest analysis for UBS Group. Despite the new US banking licence and a proposed cancellation of 63,776,550 repurchased shares, momentum has cooled, with a 30 day share price return of 10.34% decline and a year to date share price return of 22.95% decline, even as the 5...
SWX:COPN
SWX:COPNPharmaceuticals

Cosmo Pharmaceuticals (SWX:COPN) Valuation Check As NVIDIA GTC AI Conference Spotlight Nears

Cosmo Pharmaceuticals at NVIDIA GTC: Why This AI Conference Matters for Investors Cosmo Pharmaceuticals (SWX:COPN) is set to present at the NVIDIA GTC AI Conference on March 19 in San Jose, putting its MedTech AI capabilities and GI Genius platform in front of a focused AI audience. See our latest analysis for Cosmo Pharmaceuticals. Cosmo’s share price has had a weak short term run, with a 30 day share price return of 33.31% decline and a year to date decline of 24.57%. However, the 1 year...
SWX:IFCN
SWX:IFCNElectronic

INFICON Holding’s Valuation After Annual Earnings Reveal Stable Sales But Softer Profitability

Earnings event puts INFICON’s 2025 profitability in focus INFICON Holding (SWX:IFCN) has released full year 2025 results, reporting sales of US$673.72 million compared with US$670.95 million a year earlier. Net income was US$85.82 million, down from US$112.75 million. This shift has put profit trends under closer scrutiny for shareholders. See our latest analysis for INFICON Holding. The earnings release, which showed relatively steady sales but a lower net income, comes as INFICON’s 1 year...
SWX:MED
SWX:MEDMedical Equipment

A Look At Medartis Holding (SWX:MED) Valuation After Earnings Growth And Recent Share Price Move

Earnings event puts Medartis Holding (SWX:MED) in focus Medartis Holding (SWX:MED) is back on investors’ radar after reporting full year 2025 results, with higher sales, net income and earnings per share, followed by a special call on the same day. See our latest analysis for Medartis Holding. At a share price of CHF83.0, the stock has a 1 day share price return of 4.93% but a 30 day share price return that reflects a 12.17% decline. The 1 year total shareholder return of 9.35% suggests...